-
NBA legend Jordan in court as NASCAR anti-trust case begins
-
How coaches reacted to 2026 World Cup draw
-
Glasgow down Sale as Stomers win at Bayonne in Champions Cup
-
Trump takes aim at Europe in new security strategy
-
Witness in South Africa justice-system crimes probe shot dead
-
Tuchel urges England not to get carried away plotting route to World Cup glory
-
Russian ambassador slams EU frozen assets plan for Ukraine
-
2026 World Cup draw is kind to favorites as Trump takes limelight
-
WHO chief upbeat on missing piece of pandemic treaty
-
US vaccine panel upends hepatitis B advice in latest Trump-era shift
-
Ancelotti says Brazil have 'difficult' World Cup group with Morocco
-
Kriecmayr wins weather-disrupted Beaver Creek super-G
-
Ghostwriters, polo shirts, and the fall of a landmark pesticide study
-
Mixed day for global stocks as market digest huge Netflix deal
-
England boss Tuchel wary of 'surprise' in World Cup draw
-
10 university students die in Peru restaurant fire
-
'Sinners' tops Critics Choice nominations
-
Netflix's Warner Bros. acquisition sparks backlash
-
Frank Gehry: five key works
-
US Supreme Court to weigh Trump bid to end birthright citizenship
-
Frank Gehry, master architect with a flair for drama, dead at 96
-
'It doesn't make sense': Trump wants to rename American football
-
A day after peace accord signed, shelling forces DRC locals to flee
-
Draw for 2026 World Cup kind to favorites as Trump takes center stage
-
Netflix to buy Warner Bros. in deal of the decade
-
US sanctions equate us with drug traffickers: ICC dep. prosecutor
-
Migration and crime fears loom over Chile's presidential runoff
-
French officer charged after police fracture woman's skull
-
Fresh data show US consumers still strained by inflation
-
Eurovision reels from boycotts over Israel
-
Trump takes centre stage as 2026 World Cup draw takes place
-
Trump all smiles as he wins FIFA's new peace prize
-
US panel votes to end recommending all newborns receive hepatitis B vaccine
-
Title favourite Norris reflects on 'positive' Abu Dhabi practice
-
Stocks consolidate as US inflation worries undermine Fed rate hopes
-
Volcanic eruptions may have brought Black Death to Europe
-
Arsenal the ultimate test for in-form Villa, says Emery
-
Emotions high, hope alive after Nigerian school abduction
-
Another original Hermes Birkin bag sells for $2.86 mn
-
11 million flock to Notre-Dame in year since rising from devastating fire
-
Gymnast Nemour lifts lid on 'humiliation, tears' on way to Olympic gold
-
Lebanon president says country does not want war with Israel
-
France takes anti-drone measures after flight over nuclear sub base
-
Signing up to DR Congo peace is one thing, delivery another
-
'Amazing' figurines find in Egyptian tomb solves mystery
-
Palestinians say Israeli army killed man in occupied West Bank
-
McLaren will make 'practical' call on team orders in Abu Dhabi, says boss Brown
-
Norris completes Abu Dhabi practice 'double top' to boost title bid
-
Chiba leads Liu at skating's Grand Prix Final
-
Meta partners with news outlets to expand AI content
Nobel scientist uncovered tiny genetic switches with big potential
Harvard geneticist Gary Ruvkun vividly remembers the late-night phone call with his longtime friend and now 2024 Nobel Prize in Medicine co-laureate Victor Ambros, when they made their groundbreaking discovery of genetic switches that exist across the tree of life.
It was the early 1990s. The pair, who had met a decade earlier and bonded over their fascination with an obscure species of roundworm, were exchanging datapoints at 11 pm -- one of the rare moments Ambros could steal away from tending to his newborn baby.
"It just fit together like puzzle pieces," Ruvkun told AFP in an interview from his home in a Boston suburb, shortly after learning of the award on Monday. "It was a eureka moment."
What they had uncovered was microRNA: tiny genetic molecules that act as key regulators of development in animals and plants, and hold the promise of breakthroughs in treating a wide range of diseases in the years ahead.
Although these molecules are only 22 "letters" long -- compared to the thousands of lines of code in regular protein-coding genes -- their small size belies their critical role as molecular gatekeepers.
"They turn off target genes," Ruvkun explained.
"It's a little bit like how astronomy starts with looking at the visible spectrum, and then people thought 'If we look with X rays, we can see much higher energy events,'" he added.
"We were looking at genetics at much smaller scales than it had been looked at before."
- Dismissed at first -
Their discovery had its roots in early investigations into C. elegans, a one-millimeter-long roundworm.
Ambros and Ruvkun were intrigued by the interplay between two genes that seemed to disrupt the worm's normal development -- causing them either to stay in a juvenile state or acquire adult features prematurely.
The genetic information contained in all our cells flows from DNA to messenger RNA (mRNA) through a process called transcription, and then on to the cellular machinery where it provides instructions on which proteins to create.
It's through this process, understood since the mid-20th century, that cells become specialized and carry out different functions.
But Ambros and Ruvkun, who began their work in the same lab before moving to different institutions, discovered a fundamentally new pathway for regulating gene activity through microRNAs, which control gene expression after transcription.
They published their findings in back-to-back papers in Cell in 1993, but at first, the discovery was dismissed as an esoteric detail, likely irrelevant to mammals.
"We were considered an oddity in the world of developmental biology," Ruvkun recalled. Even he had little idea their work would one day be celebrated by the wider scientific community.
That all changed in 2000 when Ruvkun's lab discovered another microRNA that was present throughout the tree of life -- from roundworms to mollusks, chickens, and humans.
- 'Celebrating like crazy' -
At the time, the human genome was still being mapped, but the portion that was complete was available to researchers.
"I think it was probably one-third done, and I could already see (the new microRNA) in that one-third of the human genome," said Ruvkun. "That was a surprise!"
Since then, the microRNA field has exploded, with more than 170,000 citations currently listed in biomedical literature.
More than 1,000 microRNAs have been identified in human DNA, and some are already being used to better understand tumor types and develop treatments for people with chronic lymphocytic leukemia.
Trials are also underway to develop microRNAs as treatments for heart disease.
On the morning of their Nobel win, the two old friends "Facetimed and high-fived," Ruvkun said. "It's magnificent, and we're going to be celebrating like crazy."
L.Torres--PC